Kameda

Kamada is a commercial-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of specialty plasma-derived therapeutics. The company's flagship product, Glassia, was the first liquid, ready-to-use intravenous alpha-1 antitrypsin (AAT) approved by the FDA for the treatment of AAT deficiency. Kamada maintains a diverse portfolio of FDA-approved products, including Kedrab for rabies post-exposure prophylaxis and several hyperimmune globulins acquired from BPL and Saol Therapeutics. The company is also advancing a clinical pipeline focused on an inhaled formulation of AAT for the treatment of AAT deficiency and intravenous AAT for inflammatory and autoimmune conditions such as Graft-versus-Host Disease.